Walpar Nutritions
WALPAR NSE
Walpar Nutritions
HealthcareNSE: WALPAR Pharmaceuticals & Biotechnology
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹21.03 Cr
Volatility
Low Risk
P/E Ratio
7.2
EBITDA
₹6.90 Cr
Return on Equity
14.48%
Debt to Equity
0.89
Book Value
₹20.13
EPS
₹1.63
52W High
₹50.6
52W Low
₹21.25
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Stock is trading at 1.11 times its book value
Weaknesses
2- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 13.7% over last 3 years.
Growth Rate
Revenue Growth
9.72% lower than
3Y
Net Income Growth
14.29% lower than
3Y
Cash Flow Change
-54.93% higher than
3Y
ROE
-0.28% lower than
3Y
ROCE
-13.58% lower than
3Y
EBITDA Margin (Avg.)
5.29% lower than
3Y
Quarterly Results
| Particulars | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.98 | 13.98 | 12.78 | 16.52 | 18.62 | 31.14 | 31.38 | 32.53 | 39.24 | 36.49 | 42.3 |
| Expenses | 13.47 | 13.47 | 12.27 | 15.52 | 16.12 | 29.15 | 28.62 | 29.89 | 36.16 | 33.55 | 38.58 |
| Operating Profit | 0.51 | 0.51 | 0.51 | 1 | 2.5 | 1.99 | 2.76 | 2.64 | 3.08 | 2.94 | 3.72 |
| OPM % | 3.65% | 3.65% | 3.99% | 6.05% | 13.43% | 6.39% | 8.8% | 8.12% | 7.85% | 8.06% | 8.79% |
| Other Income | 0.04 | 0.04 | -0.02 | 0.05 | 0.27 | 0.06 | 0.16 | 0.31 | -0.04 | 0.13 | 0.13 |
| Interest | 0.25 | 0.25 | 0.24 | 0.44 | 0.36 | 0.33 | 0.34 | 0.26 | 0.03 | 0.3 | 0.5 |
| Depreciation | 0.13 | 0.13 | 0.15 | 0.84 | 1.07 | 0.92 | 0.89 | 0.88 | 0.94 | 1 | 1.02 |
| PBT | 0.17 | 0.17 | 0.1 | -0.23 | 1.34 | 0.8 | 1.69 | 1.81 | 2.07 | 1.77 | 2.33 |
| Tax % | 29.41% | 29.41% | -130% | 39.13% | 15.67% | 20% | 23.08% | 22.1% | 32.85% | 15.25% | 27.04% |
| Net Profit | 0.12 | 0.12 | 0.24 | -0.33 | 1.14 | 0.65 | 1.29 | 1.41 | 1.39 | 1.5 | 1.5 |
| EPS in Rs | 0.19 | 0.14 | 0.27 | -0.42 | 1.07 | 0.43 | 1.26 | 1.37 | 1.11 | 1.37 | 1.26 |
Profit & Loss
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 6.07 | 26.76 | 35.14 | 62.52 | 71.76 | 78.77 |
| Expenses | 5.61 | 25.74 | 31.65 | 57.77 | 66.04 | 72.11 |
| Operating Profit | 0.46 | 1.02 | 3.49 | 4.75 | 5.72 | 6.66 |
| OPM % | 7.58% | 3.81% | 9.93% | 7.6% | 7.97% | 8.45% |
| Other Income | 0 | 0.02 | 0.32 | 0.22 | 0.27 | 0.26 |
| Interest | 0.18 | 0.48 | 0.79 | 0.67 | 0.29 | 0.8 |
| Depreciation | 0.12 | 0.28 | 1.91 | 1.81 | 1.82 | 2.02 |
| PBT | 0.16 | 0.28 | 1.11 | 2.49 | 3.88 | 4.1 |
| Tax % | 6.25% | -32.14% | 27.03% | 22.09% | 27.84% | 21.71% |
| Net Profit | 0.15 | 0.36 | 0.81 | 1.94 | 2.79 | 3 |
| EPS in Rs | 0.22 | 0.42 | 0.65 | 1.68 | 2.47 | 2.63 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity Capital | 3.34 | 4.54 | 4.54 | 4.7 | 9.39 | 9.39 |
| Reserves | 1.44 | 6.45 | 7.17 | 9.49 | 7.17 | 9.51 |
| Borrowings | 7.49 | 7.25 | 10.3 | 8.3 | 7.85 | 16.77 |
| Other Liabilities | 5.73 | 9.85 | 12.29 | 14.67 | 22.98 | 30.4 |
| Total Liabilities | 18 | 28.09 | 34.3 | 37.16 | 47.39 | 66.07 |
| Fixed Assets | 1.7 | 2.01 | 10.13 | 10.2 | 10.65 | 12.21 |
| CWIP | 1.22 | 4.48 | 0.02 | 0.02 | 0.03 | 0.05 |
| Investments | 0 | 0.49 | 0.02 | 1.88 | 1.88 | 2.88 |
| Other Assets | 15.08 | 21.11 | 24.13 | 25.06 | 34.83 | 50.93 |
| Total Assets | 18 | 28.09 | 34.3 | 37.16 | 47.39 | 66.07 |
Cash Flow
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | -0.31 | -1.08 | 1.1 | 5.35 | 4.06 | 1.83 |
| Investing | -2.02 | -6.14 | -3.44 | -3.61 | -2.3 | -6.57 |
| Financing | 2.95 | 6.71 | 2.42 | -1.77 | -0.68 | 8.08 |
| Net Cash Flow | 0.62 | -0.51 | 0.07 | -0.03 | 1.08 | 3.34 |
| Free Cash Flow | -2.17 | -4.92 | -4.14 | 3.48 | 1.78 | -1.76 |
| CFO/OP | -67 | -99 | 34 | 116 | 82 | 41 |
Ratios
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor Days | 431 | 124 | 130 | 78.46 | 108 | 109 |
| Inventory Days | 369 | 103 | 129 | 67.15 | 67.85 | 93.74 |
| Days Payable | 455 | 135 | 144 | 72.94 | 109 | 136 |
| Cash Conversion Cycle | 344 | 92.41 | 114 | 72.67 | 67.07 | 66.09 |
| Working Capital Days | 316 | 61.65 | 87.87 | 43.55 | 42.17 | 40.68 |
| ROCE % | — | 4.85% | 8.78% | 12.75% | 16.08% | 14.84% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Walpar Nutritions insights
29 extracted metrics + investor summaries across FY21–FY26.
Documents
1
Copy of Newspaper Publication
31 Aug - Submitted newspaper ads for 6th AGM; book closure 16-23 Sept 2026, e-voting 20-22 Sept 2026. 31 Aug - Submitted newspaper ads for 6th AGM; book closure 16-23 Sept 2026, e-voting 20-22 Sept 2026.
2
Appointment
29 Aug - Board approved auditor appointment, four director reappointments, related-party transactions, and AGM on 23 September 2026. 29 Aug - Board approved auditor appointment, four director reappointments, related-party transactions, and AGM on 23 September 2026.
3
Outcome of Board Meeting
29 Aug - Board approved auditor appointment, four director reappointments, related-party transactions, and AGM on 23 September 2026. 29 Aug - Board approved auditor appointment, four director reappointments, related-party transactions, and AGM on 23 September 2026.
4
Change in Auditors
29 Aug - Board appointed A Y & Company auditors, reappointed four independent directors, approved RPTs, AGM on 23 Sep 2026. 29 Aug - Board appointed A Y & Company auditors, reappointed four independent directors, approved RPTs, AGM on 23 Sep 2026.
5
Shareholders meeting
29 Aug - Walpar Nutritions submitted FY2025-26 annual report; AGM on 23 Sep 2026, with RP transactions up to Rs 100 crore each. 29 Aug - Walpar Nutritions submitted FY2025-26 annual report; AGM on 23 Sep 2026, with RP transactions up to Rs 100 crore each.
Frequently Asked Questions about Walpar Nutritions
What does Walpar Nutritions Ltd do?
Incorporated in 2009, Walpar Nutrition Ltd develops and manufactures various pharmaceutical products.[1]
Where is Walpar Nutritions Ltd (WALPAR) listed?
Walpar Nutritions Ltd trades as WALPAR on the NSE.
Which sector does Walpar Nutritions Ltd belong to?
Walpar Nutritions Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Walpar Nutritions Ltd?
Walpar Nutritions Ltd has a market capitalisation of ₹21.03 Cr, which places it in the Small Cap band.
What is the PE ratio of Walpar Nutritions Ltd?
Walpar Nutritions Ltd trades at a PE ratio of 7.20, on earnings per share of ₹1.63, against a book value of ₹20.13 per share.
What is the 52-week high and low of Walpar Nutritions Ltd?
Over the last 52 weeks Walpar Nutritions Ltd has traded between ₹21.25 and ₹50.6.
What is the Return on Equity (ROE) of Walpar Nutritions Ltd?
Walpar Nutritions Ltd reported a return on equity of 14.48%. Its debt-to-equity ratio is 0.89.
Company Information
Incorporated in 2009, Walpar Nutrition Ltd develops and manufactures various pharmaceutical products.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/WALPAR.md for Walpar Nutritions Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.